Phase III Clinical Trial to Evaluate the Efficacy and Safety of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke???SAIL???- a Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial
Latest Information Update: 28 Nov 2025
At a glance
- Drugs SHPL 49 (Primary)
- Indications Ischaemic stroke
- Focus Registrational; Therapeutic Use
- Acronyms SAIL
- Sponsors Shanghai Hutchison Pharmaceuticals
Most Recent Events
- 28 Nov 2025 New trial record